Skip to main content
Sun Pharmaceutical Industries Ltd. logo

Sun Pharmaceutical Industries Ltd. — Investor Relations & Filings

Ticker · SUNPHARMA ISIN · INE044A01036 LEI · 335800KJ7GE29LB4SS73 BSE.NS Manufacturing
Open in API
Filings indexed 1,413 across all filing types
Latest filing 2025-04-07 Regulatory Filings
Country IN India
Listing BSE.NS SUNPHARMA

About Sun Pharmaceutical Industries Ltd.

https://sunpharma.com/

Sun Pharmaceutical Industries Ltd. is a global leader in specialty generic pharmaceuticals, focused on developing, manufacturing, and marketing a comprehensive range of pharmaceutical formulations and active pharmaceutical ingredients (APIs). The company’s extensive portfolio covers diverse therapeutic segments, including cardiology, psychiatry, neurology, gastroenterology, ophthalmology, dermatology, and orthopedics. It provides high-quality, affordable medicines across more than 100 markets worldwide, serving both chronic and acute care needs. A significant emphasis is placed on research and development to produce complex generics and innovative specialty products. The organization maintains a robust global manufacturing footprint, operating facilities that comply with stringent international regulatory standards. Its offerings encompass generics, branded generics, specialty medications, and over-the-counter products, aimed at improving patient outcomes globally.

Recent filings

Filing Released Lang Actions
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release dated April 7, 2025, from Sun Pharmaceutical Industries Limited announcing the launch of a novel drug, Fexuclue (Fexuprazan), in India for the treatment of Erosive Esophagitis. It includes details about the drug, clinical study results, company background, and contact information. There are no financial statements, regulatory filings, voting results, or management changes. The document is promotional and informational about a product launch rather than a financial or regulatory report. It is not an Annual Report, Earnings Release, or any other financial filing. It is a press release announcing a new product introduction to the market, which fits best under the category of Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2025-04-07 English
Retirement
Board/Management Information Classification · 100% confidence The document is a formal announcement from Sun Pharmaceutical Industries Limited regarding changes in the Board of Directors and the Audit Committee. It specifically mentions the retirement of Mr. Sanjay Asher as an Independent Director and the appointment of Ms. Rama Bijapurkar to the Audit Committee. The document includes regulatory references to SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and provides details in an annexure as required for such disclosures. The content is focused on management changes and does not contain financial data, earnings, or other report types. The document length is 3031 characters, which is relatively short and typical for a management change announcement. Therefore, the appropriate classification is Board/Management Information (MANG).
2025-03-31 English
General Updates
Regulatory Filings Classification · 95% confidence The document is a short communication informing stock exchanges about an update related to an investee company ceasing operations. It references a previous investment announcement but does not contain financial statements, detailed analysis, or a full report. The document is an official regulatory announcement under SEBI regulations, providing an update rather than a full report or detailed financial disclosure. The length is short (1384 characters), and it serves as a notification to the exchanges. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-03-26 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a short announcement from Sun Pharmaceutical Industries Limited regarding the closure of the trading window in compliance with the company's Code of Conduct for Prohibition of Insider Trading. It specifies the trading window closure period related to the upcoming declaration of audited financial results for the fiscal year ended March 31, 2025. There is no financial data, detailed report, or presentation included. The document is an announcement about trading restrictions ahead of financial results, not the results or report themselves. The length is only 1290 characters, indicating it is a brief notice rather than a full report. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2025-03-25 English
General Updates
M&A Activity Classification · 95% confidence The document is a short announcement dated March 18, 2025, informing about the completion of a 100% acquisition of Antibe Therapeutics Inc. by a subsidiary of Sun Pharmaceutical Industries Limited. It references a prior intimation dated January 16, 2025, and is filed under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which relates to disclosures about material events. The content is an update on an acquisition transaction, not a full merger filing or tender offer document. The document length is only 1310 characters, indicating it is a brief announcement rather than a detailed report. Therefore, the appropriate classification is M&A Activity (TAR), which covers announcements and documents related to merger proposals or takeover bids.
2025-03-18 English
General Updates
Regulatory Filings
2025-03-10 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.